Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects

Phase 1 Completed 140 enrolled Assistance Publique - Hôpitaux de Paris

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (\*2) associated with CYP2C19 deficiency and non responders to the usual regimen of 75 mg once daily

Timeline

Start: 2007-01
Primary completion: 2009-01
Completion: 2009-01

Publications

Results Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006 Oct 1;108(7):2244-7. doi: 10.1182/blood-2006-04-013052. Epub 2006 Jun 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clopidogrel	Small molecule	75 mg	—
Subject	Clopidogrel	Small molecule	150 mg	—

Indications

No indication recorded.